- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04425538
A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
Study Overview
Detailed Description
The investigators hypothesize that early institution of TNFα inhibitor therapy in patients with severe COVID-19 infections will prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality. To address this hypothesis, a prospective, single center, phase 2 trial is proposed to assess the efficacy of infliximab or infliximab-abda in hospitalized adult patients with severe or critical COVID-19. Observations from this study will inform the conduct of prospective randomized controlled studies to follow.
Infliximab and Infliximab-abda are TNFα inhibitors currently FDA-approved for the treatment of autoimmune disorders, including Crohn's disease and rheumatoid arthritis. The risks and adverse reactions are described in the approved prescribing information for infliximab (or infliximab-abda). Infliximab will be used when available. Should infliximab be unavailable in the pharmacy, infliximab-abda, a biosimilar, will be used.
Treatment with infliximab or infliximab-abda 5mg/kg IV should ideally be administered within 6 hours of enrollment, and no more than 24 hours following enrollment. Pre-medication with Tylenol 650 mg once 30 minutes prior to infusion would be recommended. Other pre-medications may be given at the discretion of the treating physician. These include diphenhydramine 50mg by mouth, as well as prednisone 20mg by mouth, both given 30 minutes prior to infusion. Pulse and blood pressure should be monitored every 30 minutes during the infusion, and patients should be monitored for at least 30 minutes following the infusion.
Retreatment with infliximab is permitted at treating physician discretion 7-21 days following primary therapy and based on initial response; the usual treatment schedule is every 2 weeks, this interval is not strictly enforced given the uncertainty of outcomes with primary therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 years or older
- Able to provide informed consent
- Hospitalized adult patients with pneumonia evidenced by chest X-ray or CT scan
- Laboratory (RT-PCR) confirmed infection with 2019-nCoV or strongly suspected to be infected with SARS-COV2 with confirmation studies pending
And at least one of the following:
- Respiratory frequency ≥30/min
- Blood oxygen saturation ≤93% on RA
- Partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2) <300
- Worsening of lung involvement, defined as an increase in number and/or extension of pulmonary areas of consolidation, need for increased FiO2 to maintain stable O2 saturation, or worsening O2 saturation of >3% with stable FiO2
Exclusion Criteria:
- Treatment with any TNFα inhibitor in the past 30 days
- Known hypersensitivity to any TNFα inhibitor, murine proteins, or any component of the formulation
- Presence of any of the following abnormal laboratory values at screening: absolute neutrophil count (ANC) less than 1000 mm3, hemoglobin <8.0g/L, platelets <50,000 per mm3, or AST or ALT greater than 5 x ULN
- Known active or latent Hepatitis B
- Known or suspected active tuberculosis (TB) or a history of incompletely treated or latent TB.
- Pregnancy
- Intubated for >48hours
- Patients with uncontrolled systemic bacterial or fungal infections (Patients with a history of positive bacterial or fungal cultures but on enrollment are on appropriate therapy with negative repeat cultures may be enrolled)
Serious co-morbidity, including:
- Myocardial infarction (within last month)
- Moderate or severe heart failure (New York Heart Association (NYHA) class III or IV)
- Acute stroke (within last month)
- Uncontrolled malignancy
- Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular filtration rate (eGFR) < 30 ml /min/1.73 m^2) at baseline
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Infliximab
All patients enrolled into this trial will be assigned to the Infliximab arm.
Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.
|
Either infliximab or infliximab-abda will be used at the discretion of the investigator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Improvement in Oxygenation
Time Frame: 28 Days
|
Time to improvement in oxygenation (increase in SpO2/FiO2 of 50 or greater compared to the baseline SpO2/FiO2)
|
28 Days
|
Number of p[Atients With Improvement in Oxygenation
Time Frame: 28 Days
|
Number of participants who showed improvement in oxygenation (increase in SpO2/FiO2 of 50 or greater compared to the baseline SpO2/FiO2)
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
28-Day Survival Status
Time Frame: 28 Days
|
Number of patients who were confirmed to be alive 28 days from enrollment onto the study.
|
28 Days
|
Duration of Supplemental Oxygen Administration by Nasal Cannula
Time Frame: 28 Days
|
Duration of supplemental oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device
|
28 Days
|
Duration of Non-invasive Ventilation or by Non-rebreather Mask or High-flow Nasal Cannula
Time Frame: 28 Days
|
Duration of non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula
|
28 Days
|
Number of Patients Requiring Mechanical Ventilation
Time Frame: 28 Days
|
Number of patients enrolled who required mechanical ventilation
|
28 Days
|
Number of Patients Requiring Vasopressor Support
Time Frame: 28 Days
|
Number of participants who required vasopressor support
|
28 Days
|
Number of Patients Requiring Extracorporeal Membrane Oxygenation
Time Frame: 28 Days
|
Number of patients requiring extracorporeal membrane oxygenation
|
28 Days
|
Number of Patients With Fever
Time Frame: 28 Days
|
Number of patients who exhibited fever during the study period
|
28 Days
|
Correlation of Dynamic Changes in IP-10 to Cytokine Profile
Time Frame: 3 Days
|
Correlation of dynamic changes in IP-10 to cytokine profile between day 3 and baseline
|
3 Days
|
Duration of Hospitalization
Time Frame: 28 Days
|
Duration of hospitalization
|
28 Days
|
Number of Patients Who Developed Secondary Infections
Time Frame: 28 Days
|
Number of patients who developed secondary infections
|
28 Days
|
Number of Patients Requiring Supplemental Oxygen Administration by Nasal Cannula
Time Frame: 28 Days
|
Incidence of supplemental oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device
|
28 Days
|
Duration of Mechanical Ventilation
Time Frame: 28 Days
|
duration of use of mechanical ventilation (for patients requiring mechanical ventilation)
|
28 Days
|
Number of Patients Requiring Non-invasive Ventilation or by Non-rebreather Mask or High-flow Nasal Cannula
Time Frame: 28 Days
|
Number of participants who required non-invasive ventilation or by non-rebreather mask or high-flow nasal cannula
|
28 Days
|
Assessment of Cytokine and Inflammatory Profile at Baseline
Time Frame: Baseline
|
Assessment of cytokine and inflammatory profile at baseline (TNFα, IL-1b, IL-2, IL-6, ferritin) after therapy
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Paul Mathew, MD, Tufts Medical Center
Publications and helpful links
General Publications
- Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew P. Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-alpha antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. medRxiv. 2021 Jun 2:2021.05.29.21258010. doi: 10.1101/2021.05.29.21258010. Preprint.
- Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew P. Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFalpha-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. J Clin Transl Sci. 2021 Jun 25;5(1):e146. doi: 10.1017/cts.2021.805. eCollection 2021.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000564
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUnknown
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupTerminatedRheumatoid Arthritis
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityCompletedRheumatoid Arthritis | Crohn's Disease | Ulcerative Colitis | Psoriatic Arthritis | Spondyloarthritis | Psoriasis ChronicNorway
-
PfizerCompleted
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara Health... and other collaboratorsRecruiting
-
NYU Langone HealthWithdrawnInflammatory Bowel Disease
-
PfizerCompletedPsoriasis Vulgaris | Pustular Psoriasis | Psoriasis Arthropathica | Erythrodermic PsoriasisJapan
-
Asan Medical CenterNot yet recruitingCrohn Disease | Therapeutic Drug Monitoring | Infliximab | Perianal Fistula Due to Crohn's Disease | Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score
-
European Organisation for Research and Treatment...CompletedMyelodysplastic SyndromesFrance, Belgium, Netherlands, Czech Republic, Italy, Germany
-
Janssen Research & Development, LLCJanssen Biologics BVCompletedUlcerative ColitisUnited States, France, United Kingdom, Belgium, Switzerland, Israel, Canada, Australia, Netherlands, New Zealand, Austria, Germany, Denmark, Czechia, Argentina